Deal Structure and Key Highlights

Global healthcare distribution giant McKesson Corporation (NYSE: MCK) has completed a transaction to sell a minority stake in its Medical-Surgical Solutions (MMS) business, one of its core business units, to Apollo Global Management (NYSE: APO), a private equity firm. In this deal, Apollo acquired approximately $1.25 billion in convertible preferred equity, securing a 13% stake in the MMS business. This values the entire enterprise of MMS at approximately $13 billion. McKesson will continue to consolidate the financial results of MMS while retaining a controlling interest and management control until the planned spin-off and IPO. This strategic move can be interpreted as an effort to generate significant cash flow by divesting non-core assets and improving its financial health.

Strategic Spin-off and IPO Timeline

This stake sale is more than just a capital raise; it is a stepping stone for McKesson to execute its previously announced plan for an Initial Public Offering (IPO) of the MMS business in May 2025. McKesson has been preparing for the spin-off of this division, and the proceeds from the sale will be used to build infrastructure for the upcoming IPO and to pay down debt. While the specific timeline for the IPO is subject to market conditions and regulatory approvals, industry analysts are targeting the second half of 2027. This proactive valuation of the stake is a strategic move to attract a higher premium from investors at the time of the IPO.

Apollo's Hybrid Investment Rationale

Apollo Global Management is a global private equity firm specializing in complex carve-out transactions for large corporations in the healthcare and medical technology sectors. Through its hybrid platform, Apollo will provide flexible capital to MMS, which is in the process of preparing for an IPO, and will act as a strategic partner to facilitate its smooth transition as an independent entity. The company likely sees significant growth potential, as the distribution market, which had been somewhat stagnant due to supply chain disruptions and changes in demand following the COVID-19 pandemic, is gradually recovering.

Restructuring of the Medical Device Distribution Market and McKesson's Future

The MMS business accounts for approximately 3.2% of McKesson's annual revenue of $403.4 billion (based on fiscal year 2026) and has consistently generated strong quarterly results of approximately $2.9 to $3 billion. Through this spin-off, McKesson plans to streamline its corporate portfolio and focus its resources on its oncology and biopharma solutions businesses, which have higher margins and greater growth potential. As a result, major competitors in the medical device distribution sector, such as Cardinal Health and Henry Schein, are likely to consider asset optimization or similar forms of partnerships. Ultimately, this stake sale and the subsequent independent IPO are expected to be a major turning point that will transform the entire North American healthcare distribution supply chain.